Boston Scientific (NYSE:BSX) Stock Price Expected to Rise, Leerink Partners Analyst Says

Key Points

• Leerink Partners raised the price target for Boston Scientific (BSX) from $127.00 to $128.00, indicating a potential upside of 31.21% from its current price, while maintaining an "outperform" rating.
• Several other firms have also increased their price targets for BSX, with BTIG raising it to $132.00 and UBS Group to $135.00, all reflecting strong market confidence in the stock.
• Boston Scientific reported better-than-expected earnings with $5.06 billion in revenue and $0.75 EPS, surpassing consensus estimates and demonstrating a 22.8% increase year-over-year.

Boston Scientific (NYSE:BSX - Get Free Report) had its price target raised by investment analysts at Leerink Partners from $127.00 to $128.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has an "outperform" rating on the medical equipment provider's stock. Leerink Partners' price objective would suggest a potential upside of 31.21% from the company's current price.

A number of other research firms also recently commented on BSX. BTIG Research increased their price objective on shares of Boston Scientific from $127.00 to $132.00 and gave the company a "buy" rating in a research note on Wednesday. Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Wells Fargo & Company boosted their price objective on Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a report on Thursday, July 24th. UBS Group increased their target price on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a report on Thursday, July 24th. Finally, Royal Bank Of Canada reiterated an "outperform" rating and issued a $125.00 price target on shares of Boston Scientific in a report on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $120.50.

Boston Scientific Stock Performance

Boston Scientific stock opened at $97.55 on Wednesday. The firm has a market capitalization of $144.54 billion, a PE ratio of 58.07, a price-to-earnings-growth ratio of 2.34 and a beta of 0.65. Boston Scientific has a one year low of $80.64 and a one year high of $109.50. The stock's 50 day moving average price is $103.53 and its 200 day moving average price is $102.13. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific's revenue for the quarter was up 22.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, sell-side analysts expect that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $105.43, for a total transaction of $5,271,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $18,802,597.06. This trade represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 124,214 shares of company stock valued at $13,048,957. 0.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. HM Payson & Co. boosted its position in Boston Scientific by 1.4% during the 1st quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock worth $694,000 after acquiring an additional 98 shares during the period. Riverwater Partners LLC raised its stake in shares of Boston Scientific by 3.3% during the second quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider's stock valued at $333,000 after purchasing an additional 98 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management lifted its holdings in Boston Scientific by 3.8% in the second quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider's stock worth $291,000 after purchasing an additional 99 shares during the period. IVC Wealth Advisors LLC grew its position in Boston Scientific by 4.9% in the 2nd quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider's stock valued at $236,000 after buying an additional 102 shares in the last quarter. Finally, Park Square Financial Group LLC increased its stake in Boston Scientific by 5.2% during the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock valued at $208,000 after buying an additional 103 shares during the period. 89.07% of the stock is owned by institutional investors.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.